Targeted therapies in cancer

BioDrugs

Volumn 24, Issue 2, 2010, Pages 77-88

  Ciavarella, Sabino ^a   Milano, Annalisa ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cancer; Monoclonal antibodies, general; Protein kinase inhibitors, general; Research and development; Stem cell targets

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPRATUZUMAB; GALIXIMAB; GEMTUZUMAB OZOGAMICIN; IMATINIB; IPILIMUMAB; LONAFARNIB; LUMILIXIMAB; MDX 1106; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; NIMOTUZUMAB; OREGOVOMAB; PANITUMUMAB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RITUXIMAB; SORAFENIB; STEM CELL FACTOR; TELOMERASE; TIPIFARNIB; TRASTUZUMAB; TRU 016; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE INTERVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; GLIOMA; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MITOSIS INHIBITION; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 77749239979     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11530830-000000000-00000     Document Type: Review

References (114)

1. Infield GB. Disaster at Bari. New York: Mcmillan, 1971
2. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8 (10): 755-68
3. FDA-approved drugs. Boston (MA): CenterWatch, 2007 [online]. Available from URL: http://www.centerwatch.com/drug-information/fda-approvals [Accessed 2010 Jan 22]
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1): 57-70
5. Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment of CML and GIST. Ann Hematol 2004; 83 Suppl. 1: S65-6
6. Soverini S, Martinelli G, Iacobucci I, et al. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 2008; 8 (6): 853-64
7. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers [letter]. Science 2003; 300 (5621): 949
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351 (9114): 1451-67
9. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102 (1): 37-46
10. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 Suppl. 4: 2-8
11. Menard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22 (42): 6570-8
12. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358 (11): 1160-74
13. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-82
14. Shields JM, Pruitt K, McFall A, et al. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000; 10 (4): 147-54
15. Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition to Ras protein isthe critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 1992; 89 (14): 6403-7
16. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23 (5): 1028-43
17. Ng R, Chen EX. Sorafenib (BAY 43-9006): review of clinical development. Curr Clin Pharmacol 2006; 1 (3): 223-8
18. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1 (3): 397-403
19. Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia 2007; 21 (1): 44-52
20. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003; 3 (7): 643-51
21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9 (6): 669-76
22. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61 (13): 5090-101
23. Ribatti D, Vacca A. Novel therapeutic approaches targeting vascular endothelial growth factor and its receptors in haematological malignancies. Curr Cancer Drug Targets 2005; 5 (8): 573-8
24. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2): 4258s-62s
25. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303 (5659): 848-51
26. Jones E, Pu H, Kyprianou N. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009; 13 (2): 227-34
27. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971; 46 (2): 411-22
28. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3 (7): 730-7
29. Galderisi U, Cipollaro M, Giordano A. Stem cells and brain cancer. Cell Death Differ 2006; 13 (1): 5-11
30. Pfeiffer MJ, Schalken JA. Stem Cell Characteristics in Prostate Cancer Cell Lines. Eur Urol. Epub 2009 Jan 19
31. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and adistinct molecular signature. Cancer Res 2009; 69 (4): 1302-13
32. Groszer M, Erickson R, Scripture-Adams DD, et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001; 294 (5549): 2186-9
33. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell 2008; 15 (6): 801-12
34. Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13 (14): 4042-5
35. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 2006; 17 (11): 1620-4
36. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61 (12): 4750-5
37. D'Alessandro AM, Pirsch JD, Stratta RJ, et al. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation. Transplantation 1989; 47 (2): 297-300
38. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005; 36 (1): 84-95
39. Moroney S, Pluckthun A. Modern antibody technology: the impact on drug development. In: Knaeblein J, editor. Modern biopharmaceuticals. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005: 1147-86
40. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1 (2): 118-29
41. Zhang N, Khawli LA, Hu P, et al. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005; 11 (16): 5971-80
42. Bianco R, Daniele G, Ciardiello F, et al. Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 2005; 6 (3): 275-87
43. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005; 12 (3): 243-53
44. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond toa four-dose treatment program. J Clin Oncol 1998; 16 (8): 2825-33
45. Coiffier B. First-line treatment of follicular lymphoma in the era of mono-clonal antibodies. Clin Adv Hematol Oncol 2005; 3 (6): 484-91, 505
46. Quintas-Cardama A, O'Brien S. Targeted therapy for chronic lymphocytic leukemia. Target Oncol 2009; 4 (1): 11-21
47. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24 (18): 2786-92
48. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673-84
49. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (4): 337-45
50. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. 2007 ASCO Annual Meeting Proceedings Part I, 2007. J Clin Oncol; 25 Suppl. 18S: 4000
51. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005; 69 Suppl. 3: 46-56
52. D'Adamo DR, Anderson SE, Albritton K, et al. PhaseII study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23 (28): 7135-42
53. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005; 19 (11): 1993-5
54. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999; 26 (5 Suppl. 14): 88-96
55. Raben D, Helfrich B, Chan DC, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11 (2 Pt 1): 795-805
56. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9 (4): 548-64
57. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23 (9): 1137-46
58. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6 (2): 326-34
59. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus ri-tuximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20 (10): 2453-63
60. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 to-situmomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23 (30): 7565-73
61. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352 (5): 441-9
62. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cyto-genetic responses. Blood 2003; 101 (1): 97-100
63. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safetyofimatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-80
64. Gum RJ, McLaughlin MM, Kumar S, et al. Acquisition of sensitivity of stress-activated protein kinases tothe p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 1998; 273 (25): 15605-10
65. Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998; 6 (9): 1117-28
66. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (1): 16-24
67. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178 (5): 1883-7
68. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8 (4): 303-6
69. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11 (18): 6414-21
70. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40 (2): 261-9
71. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3 (11): 1427-38
72. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused byBCR-ABL gene mutation or amplification. Science 2001; 293 (5531): 876-80
73. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127 (1): 294-9
74. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352 (8): 786-92
75. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11 (12): 1192-7
76. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006; 2 (2): 95-102
77. Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65 (8): 3025-9
78. Vlashi E, Kim K, Lagadec C, et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009; 101 (5): 350-9
79. Al-Hajj M, Becker MW, Wicha M, et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14 (1): 43-7
80. Sakariassen PO, Immervoll H, Chekenya M. Cancer stem cells asmediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007; 9 (11): 882-92
81. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007; 26 (9): 1357-60
82. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15 (9): 494-501
83. Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7 (11): 967-76
84. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8 (3): 167-79
85. Jimeno A, Feldmann G, Suarez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8 (2): 310-4
86. Eichenmuller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009; 49 (2): 482-90
87. Warzecha J, Bonke L, Koehl U, et al. The hedgehog inhibitor cyclopamine induces apoptosis in leukemic cells in vitro. Leuk Lymphoma 2008; 49 (12): 2383-6
88. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297 (5586): 1559-61
89. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432 (7015): 324-31
90. Bin Hafeez B, Adhami VM, Asim M, et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 2009; 15 (2): 452-9
91. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. Faseb J 2007; 21 (14): 3777-85
92. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007; 11 (1): 3-5
93. Gulbins E, Jekle A, Ferlinz K, et al. Physiology of apoptosis. Am J Physiol Renal Physiol 2000; 279 (4): F605-15
94. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10 (1): 35-51
95. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4 (4): 333-9
96. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98 (3): 795-804
97. Daniel D, Yang B, Lawrence DA, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110 (12): 4037-46
98. Labrinidis A, Diamond P, Martin S, et al. ApoL/TRAIL inhibits tumor growth and bone desrtuction in a murin model of multiple myeloma. Clin Cancer Res 2009; 15 (6): 1998-2009
99. Mitsiades N, Mitsiades CS, Poulaki V, et al. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs 2001; 10 (8): 1521-30
100. Balsas P, Lopez-Royuela N, Galan-Malo P, et al. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009; 77 (5): 804-12
101. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005; 5: 2-11
102. Frese S, Brunner T, Gugger M, et al. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123 (1): 168-74
103. Herbst RS, Mendolson DS, Ebbinghaus S, et al. A phase I safety and pharmacokinetic study in patients with advanced cancer treated with recombinant Apo2L/TRAIL, an apoptosis-inducing protein [abstract]. J Clin Oncol 2006; 24: 3013
104. Yee L, Fanale M, Dimick K, et al. Results of a phase Ib study of recombinant human Apo2L/TRAIL with rituximab in patients with relapsed, low-grade NHL [abstract]. Ann Oncol 2008; 19 Suppl. 4: iv161
105. Soria J, Smit EF, Khayat D, et al. Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2008; 26: 3539
106. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13 (20): 6187-94
107. Pukac L, Kanakaraj P, Humphreys R, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005; 92 (8): 1430-41
108. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25 (11): 1390-5
109. Zhang L, Zhang X, Barrisford GW, et al. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251 (1): 146-57
110. Kanzler S, Trarbach T, Heinemann V, et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC) [abstract no. 630]. 13th European Cancer Conference; 2005 Oct 30-Nov 3; Paris
111. Bonomi P, Greco A, Crawford J, et al. Results of a phase 2 trial of HGSETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent nonsmall cell lung cancer [abstract no. 1851]. 11th World Conference on Lung Cancer; 2005 Jul 3-6; Barcelona
112. She QB, Solit DB, Ye Q, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8 (4): 287-97
113. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23 (11): 2544-55
114. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23 (31): 7889-96